Systematic Review
. 2013 Aug;141(1).
doi: 10.1007/s10549-013-2666-z.

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Josh J Carlson 1 Joshua A Roth  
  • PMID: 23974828
  •     42 References
  •     72 citations


The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT) treatment decisions has been evaluated in many previous studies. However, it can be difficult to interpret the collective findings, which were conducted in diverse settings with limited sample sizes. We conducted a systematic review and meta-analysis to synthesize the results and provide insights about ODX utility. Studies, identified from PubMed, Embase, ASCO, and SABCS, were included if patients had ER+, node -, early-stage breast cancer, reported use of ODX to inform actual ACT decisions. Information was summarized and pooled according to: (1) distribution of ODX recurrence scores (RS), (2) impact of ODX on ACT recommendations, (3) impact of ODX on ACT use, and (4) proportion of patients following the treatment suggested by the ODX RS. A total of 23 studies met inclusion criteria. The distribution of RS categories was 48.8 % low, 39.0 % intermediate, and 12.2 % high (21 studies, 4,156 patients). ODX changed the clinical-pathological ACT recommendation in 33.4 % of patients (8 studies, 1,437 patients). In patients receiving ODX, receipt of ACT were: 28.2 % overall, 5.8 % low, 37.4 % intermediate, and 83.4 % high. Low RS patients were significantly more likely to follow the treatment suggested by ODX versus high RS patients RR: 1.07 (1.01–1.14) [corrected].The pooled results are consistent with most individual studies to date. The increased proportion of intermediate scores relative to original estimates may have implications for the clinical utility and cost impacts of testing. In addition, low versus high RS patients were significantly more likely to follow the ODX results, suggesting a tendency toward less aggressive treatment, despite a high ODX RS. Finally, there was a lack of studies on the impact of ODX on ACT use versus standard approaches, suggesting that additional studies are warranted.

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve.
Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
John Hornberger, Leon E Cosler, Gary H Lyman.
Am J Manag Care, 2005 May 19; 11(5). PMID: 15898220
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?
Nina Oestreicher, Scott D Ramsey, +4 authors, David L Veenstra.
Genet Med, 2005 Jul 19; 7(6). PMID: 16024969
Invited commentary: a critical look at some popular meta-analytic methods.
S Greenland.
Am J Epidemiol, 1994 Aug 01; 140(3). PMID: 8030632
Highly Cited.
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Juhi Asad, Allyson F Jacobson, +7 authors, Paul I Tartter.
Am J Surg, 2008 Sep 24; 196(4). PMID: 18809056
Impact of gene expression profiling tests on breast cancer outcomes.
Luigi Marchionni, Renee F Wilson, +4 authors, Steven N Goodman.
Evid Rep Technol Assess (Full Rep), 2008 May 07; (160). PMID: 18457476    Free PMC article.
Genomic predictors of outcome and treatment response in breast cancer.
Lara Dunn, Angela Demichele.
Mol Diagn Ther, 2009 Jun 23; 13(2). PMID: 19537843
Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.
Jennifer J Griggs, Sarah T Hawley, +8 authors, Steven J Katz.
J Clin Oncol, 2012 Aug 08; 30(25). PMID: 22869890    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Kathy S Albain, Soonmyung Paik, Laura van't Veer.
Breast, 2009 Nov 17; 18 Suppl 3. PMID: 19914534
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
Catherine M Kelly, Savitri Krishnamurthy, +4 authors, Lajos Pusztai.
Cancer, 2010 Jul 29; 116(22). PMID: 20665886
The influence of a gene expression profile on breast cancer decisions.
Leonard R Henry, Alexander Stojadinovic, +3 authors, Peter W Soballe.
J Surg Oncol, 2009 Feb 11; 99(6). PMID: 19204954
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Marleen Kok, Sabine C Linn, +11 authors, Els M J J Berns.
Breast Cancer Res Treat, 2008 Mar 04; 113(2). PMID: 18311582
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.
S Duval, R Tweedie.
Biometrics, 2000 Jul 06; 56(2). PMID: 10877304
Highly Cited.
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
John Hornberger, Rebecca Chien, Katie Krebs, Louis Hochheiser.
J Oncol Pract, 2011 Sep 03; 7(3 Suppl). PMID: 21886510    Free PMC article.
21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.
Mary Jo Lund, Marina Mosunjac, +7 authors, Ruth M O'Regan.
Cancer, 2011 Jul 02; 118(3). PMID: 21720988
Women's experiences with genomic testing for breast cancer recurrence risk.
Janice P Tzeng, Deborah Mayer, +5 authors, Noel T Brewer.
Cancer, 2010 Mar 10; 116(8). PMID: 20213682
The hazards of scoring the quality of clinical trials for meta-analysis.
P Jüni, A Witschi, R Bloch, M Egger.
JAMA, 1999 Sep 24; 282(11). PMID: 10493204
Highly Cited.
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Richard G Gray, Philip Quirke, +10 authors, David J Kerr.
J Clin Oncol, 2011 Nov 10; 29(35). PMID: 22067390
Highly Cited.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Gene expression profiling in breast cancer: a clinical perspective.
Grazia Arpino, Daniele Generali, +16 authors, Luigi Dogliotti.
Breast, 2013 Mar 07; 22(2). PMID: 23462680
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
D B Geffen, S Abu-Ghanem, +6 authors, M Koretz.
Ann Oncol, 2011 Mar 03; 22(11). PMID: 21363879
Gene expression profiling in breast cancer.
Kiran Turaga, Geza Acs, Christine Laronga.
Cancer Control, 2010 Jul 29; 17(3). PMID: 20664515
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med, 2009 Jan 07; 11(1). PMID: 19125125    Free PMC article.
Systematic review: gene expression profiling assays in early-stage breast cancer.
Luigi Marchionni, Renee F Wilson, +4 authors, Steven N Goodman.
Ann Intern Med, 2008 Feb 07; 148(5). PMID: 18252678
Systematic Review.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, +2 authors, PRISMA Group.
Ann Intern Med, 2009 Jul 23; 151(4). PMID: 19622511
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
Ido Wolf, Noa Ben-Baruch, +6 authors, Bella Kaufman.
Cancer, 2007 Dec 14; 112(4). PMID: 18076012
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
Ruth Oratz, Dev Paul, Allen L Cohn, Scot M Sedlacek.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859407    Free PMC article.
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
Johannes R Kratz, Jianxing He, +26 authors, David M Jablons.
Lancet, 2012 Jan 31; 379(9818). PMID: 22285053    Free PMC article.
Highly Cited.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Breast cancer assessment tools and optimizing adjuvant therapy.
Catherine Oakman, Libero Santarpia, Angelo Di Leo.
Nat Rev Clin Oncol, 2010 Oct 27; 7(12). PMID: 20975745
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Shmuel H Klang, Ariel Hammerman, +3 authors, John Hornberger.
Value Health, 2010 Apr 24; 13(4). PMID: 20412544
Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Jessica F Partin, Eleftherios P Mamounas.
Ann Surg Oncol, 2011 May 04; 18(12). PMID: 21537874
US insurance program's experience with a multigene assay for early-stage breast cancer.
John Hornberger, Rebecca Chien, Katie Krebs, Louis Hochheiser.
Am J Manag Care, 2011 Jun 30; 17(5 Spec No). PMID: 21711071
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Clinical and genetic predictors of prognosis in myelodysplastic syndromes.
Rafael Bejar.
Haematologica, 2014 Jun 02; 99(6). PMID: 24881041    Free PMC article.
Macroscopic stiffness of breast tumors predicts metastasis.
Joseph Fenner, Amanda C Stacer, +3 authors, Gary D Luker.
Sci Rep, 2014 Jul 02; 4. PMID: 24981707    Free PMC article.
Horizontal integration of OMIM across the medical school preclinical curriculum for early reinforcement of clinical genetics principles.
Adam C Diehl, Lauren Reader, Ada Hamosh, Joann N Bodurtha.
Genet Med, 2014 Jul 18; 17(2). PMID: 25032988    Free PMC article.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression.
Fisnik Kurshumliu, Lumturije Gashi-Luci, +2 authors, Ugur Gozalan.
World J Surg Oncol, 2014 Aug 02; 12. PMID: 25082024    Free PMC article.
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
Terri Patricia McVeigh, Lauren M Hughes, +4 authors, Michael J Kerin.
Eur J Cancer, 2014 Sep 23; 50(16). PMID: 25240289    Free PMC article.
Unbiased approaches to biomarker discovery in neurodegenerative diseases.
Alice S Chen-Plotkin.
Neuron, 2014 Dec 03; 84(3). PMID: 25442938    Free PMC article.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.
Kazuhiro Ikeda, Kuniko Horie-Inoue, Satoshi Inoue.
Acta Pharmacol Sin, 2014 Dec 17; 36(1). PMID: 25500870    Free PMC article.
Closing the gap between knowledge and clinical application: challenges for genomic translation.
Wylie Burke, Diane M Korngiebel.
PLoS Genet, 2015 Feb 27; 11(2). PMID: 25719903    Free PMC article.
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Bradley M Turner, Kristin A Skinner, +6 authors, David G Hicks.
Mod Pathol, 2015 May 02; 28(7). PMID: 25932962
Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.
E M Quinn, C Fleming, M J O'Sullivan.
Ir J Med Sci, 2015 May 15; 185(2). PMID: 25971465
Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group.
Samuel L Volchenboum, Jorge Andrade, +8 authors, Elizabeth R Lawlor.
J Pathol Clin Res, 2015 Jun 09; 1(2). PMID: 26052443    Free PMC article.
Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
Niamh Conlon, Dara S Ross, +3 authors, Lee K Tan.
Breast J, 2015 Aug 15; 21(5). PMID: 26271749    Free PMC article.
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Arnold L Potosky, Suzanne C O'Neill, +8 authors, Marc D Schwartz.
Cancer, 2015 Aug 21; 121(22). PMID: 26291519    Free PMC article.
Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Maria Karsten, Michelle Stempel, +2 authors, Tari A King.
Ann Surg Oncol, 2015 Sep 06; 23(2). PMID: 26340863    Free PMC article.
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
J Natl Compr Canc Netw, 2015 Oct 21; 13(10). PMID: 26483061    Free PMC article.
The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype.
Eleanor F Need, Luke A Selth, +8 authors, Grant Buchanan.
BMC Cancer, 2015 Oct 27; 15. PMID: 26498662    Free PMC article.
Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.
Melody J Xu, Jay F Dorsey, +7 authors, Gary D Kao.
Oncologist, 2015 Nov 29; 21(1). PMID: 26614709    Free PMC article.
Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.
B Jahn, U Rochau, +7 authors, U Siebert.
Springerplus, 2015 Dec 23; 4. PMID: 26693110    Free PMC article.
Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score.
Thaer Khoury, Xiao Huang, +3 authors, Mateusz Opyrchal.
Appl Immunohistochem Mol Morphol, 2016 Jan 26; 24(10). PMID: 26808126    Free PMC article.
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model.
Joaquin Chapa, Gary An, Swati A Kulkarni.
PLoS One, 2016 Mar 31; 11(3). PMID: 27023391    Free PMC article.
Documenting Pharmacogenomic Testing with CPT Codes.
Erik Hefti, Javier G Blanco.
J AHIMA, 2016 Apr 09; 87(1). PMID: 27055343    Free PMC article.
Underutilization of gene expression profiling for early-stage breast cancer in California.
Rosemary D Cress, Yingjia S Chen, +2 authors, Kenneth W Kizer.
Cancer Causes Control, 2016 Apr 22; 27(6). PMID: 27097910    Free PMC article.
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Amila Orucevic, Robert E Heidel, John L Bell.
Breast Cancer Res Treat, 2016 May 22; 157(3). PMID: 27206678    Free PMC article.
Breast cancer multigene testing trends and impact on chemotherapy use.
G Thomas Ray, Jeanne Mandelblatt, +4 authors, Tracy A Lieu.
Am J Manag Care, 2016 Jun 09; 22(5). PMID: 27266581    Free PMC article.
Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely (®) Initiative.
Jeffrey Landercasper, Lisa Bailey, +14 authors, Steven L Chen.
Ann Surg Oncol, 2016 Jun 24; 23(10). PMID: 27334216    Free PMC article.
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Benjamin M Parsons, Jeffrey Landercasper, +3 authors, Leah L Dietrich.
Breast Cancer Res Treat, 2016 Aug 11; 159(2). PMID: 27507245    Free PMC article.
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Hannah Y Wen, Melissa Krystel-Whittemore, +7 authors, Edi Brogi.
Cancer, 2016 Aug 16; 123(1). PMID: 27526056    Free PMC article.
A strategy to identify housekeeping genes suitable for analysis in breast cancer diseases.
Tatiana M Tilli, Cláudio da Silva Castro, Jack A Tuszynski, Nicolas Carels.
BMC Genomics, 2016 Aug 17; 17(1). PMID: 27526934    Free PMC article.
Progress in the clinical detection of heterogeneity in breast cancer.
Jun-Long Song, Chuang Chen, Jing-Ping Yuan, Sheng-Rong Sun.
Cancer Med, 2016 Oct 25; 5(12). PMID: 27774765    Free PMC article.
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Hyun-Seok Kim, Christopher B Umbricht, +22 authors, Leslie Cope.
J Clin Oncol, 2016 Dec 22; 34(36). PMID: 27998227    Free PMC article.
The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.
Yun Li, Allison W Kurian, +6 authors, Timothy P Hofer.
Breast Cancer Res Treat, 2016 Dec 25; 161(3). PMID: 28012085    Free PMC article.
Low utility of Oncotype DX® in the clinic.
Luisel J Ricks-Santi, John Tyson McDonald.
Cancer Med, 2017 Feb 02; 6(3). PMID: 28145091    Free PMC article.
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577081    Free PMC article.
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Gulisa Turashvili, Joanne F Chou, +5 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jul 14; 166(1). PMID: 28702894    Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Delphine Hequet, Céline Callens, +20 authors, Roman Rouzier.
PLoS One, 2017 Oct 19; 12(10). PMID: 29045452    Free PMC article.
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Michaela Tsai, Shelly Lo, +11 authors, Hatem Soliman.
JAMA Oncol, 2017 Oct 28; 4(1). PMID: 29075751    Free PMC article.
Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
BMC Cancer, 2018 Jan 07; 18(1). PMID: 29304773    Free PMC article.
Cost Effectiveness of Gene Expression Profile Testing in Community Practice.
Young Chandler, Clyde B Schechter, +8 authors, Jeanne S Mandelblatt.
J Clin Oncol, 2018 Jan 09; 36(6). PMID: 29309250    Free PMC article.
The 21-Gene Recurrence Score in Male Breast Cancer.
Gulisa Turashvili, Monica Gonzalez-Loperena, +4 authors, Hannah Y Wen.
Ann Surg Oncol, 2018 Mar 10; 25(6). PMID: 29520654    Free PMC article.
Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.
Shigeo Yamaguchi, Shin Takahashi, +8 authors, Shunsuke Kato.
Oncotarget, 2018 Mar 28; 9(18). PMID: 29581837    Free PMC article.
Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center.
Hans-Ullrich Voelker, Lea Frey, Annette Strehl, Michael Weigel.
Int J Breast Cancer, 2018 Aug 17; 2018. PMID: 30112216    Free PMC article.
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Hans-Ullrich Völker, Michael Weigel, Annette Strehl, Lea Frey.
Diagn Pathol, 2018 Sep 02; 13(1). PMID: 30170623    Free PMC article.
Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype.
Heather D Couture, Lindsay A Williams, +6 authors, Marc Niethammer.
NPJ Breast Cancer, 2018 Sep 06; 4. PMID: 30182055    Free PMC article.
Oncotype testing in patients undergoing intraoperative radiation for breast cancer.
Kelsey E Larson, Stephanie A Valente, +7 authors, Stephen R Grobmyer.
Mol Clin Oncol, 2018 Oct 23; 9(5). PMID: 30345048    Free PMC article.
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study.
Dean A Regier, David L Veenstra, Anirban Basu, Josh J Carlson.
Pharmacoeconomics, 2019 Sep 07; 38(1). PMID: 31489595
Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry.
David K Woolf, Sonia P Li, +10 authors, Vicky Goh.
Biomark Cancer, 2019 Jun 19; 11. PMID: 31210736    Free PMC article.
Walking in the shoes of patients, not just in their genes: a patient-centered approach to genomic medicine.
Neeraj K Arora, Bradford W Hesse, Steven B Clauser.
Patient, 2014 Oct 11; 8(3). PMID: 25300612
NeTFactor, a framework for identifying transcriptional regulators of gene expression-based biomarkers.
Mehmet Eren Ahsen, Yoojin Chun, +4 authors, Supinda Bunyavanich.
Sci Rep, 2019 Sep 12; 9(1). PMID: 31506535    Free PMC article.
Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes.
Alina M Mateo, Anna M Mazor, +7 authors, Richard J Bleicher.
Clin Breast Cancer, 2019 Mar 16; 19(4). PMID: 30871966    Free PMC article.
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.
Eric Koncina, Serge Haan, Stefan Rauh, Elisabeth Letellier.
Cancers (Basel), 2020 Feb 06; 12(2). PMID: 32019056    Free PMC article.
The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
Hirah Rizki, Christopher Hillyar, Omar Abbassi, Sascha Miles-Dua.
Cureus, 2020 Mar 21; 12(3). PMID: 32195072    Free PMC article.
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Valerie E Crolley, Husam Marashi, +12 authors, Judy King.
Breast Cancer Res Treat, 2020 Mar 15; 180(3). PMID: 32170635    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study.
Yanna Zhang, Yidong Zhou, +2 authors, Qiang Sun.
Cancer Commun (Lond), 2020 Apr 16; 40(4). PMID: 32291973    Free PMC article.
Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Christopher Hillyar, Hirah Rizki, +4 authors, Simon Smith.
Cureus, 2020 May 10; 12(4). PMID: 32382456    Free PMC article.
Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
Julia E C van Steenhoven, Bianca M den Dekker, +6 authors, Thijs van Dalen.
Breast Cancer Res Treat, 2020 May 21; 182(1). PMID: 32430679    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients.
Ashley Biswal, Jacqueline Erler, +6 authors, Denise Johnson Miller.
J Clin Med Res, 2019 May 31; 11(6). PMID: 31143307    Free PMC article.
Cascaded Wx: A Novel Prognosis-Related Feature Selection Framework in Human Lung Adenocarcinoma Transcriptomes.
Bonggun Shin, Sungsoo Park, +6 authors, Keunsoo Kang.
Front Genet, 2019 Aug 06; 10. PMID: 31379926    Free PMC article.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen.
BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270    Free PMC article.
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Carolyn Cullinane, Christina Fleming, +5 authors, Henry Paul Redmond.
JAMA Netw Open, 2020 Nov 20; 3(11). PMID: 33211112    Free PMC article.
Systematic Review.
Benefits of introduction of Oncotype DX® testing.
N Green, A Al-Allak, C Fowler.
Ann R Coll Surg Engl, 2018 Oct 17; 101(1). PMID: 30322288    Free PMC article.
A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Sae Byul Lee, Junetae Kim, +8 authors, Kyung Hae Jung.
Cancer Res Treat, 2018 Nov 06; 51(3). PMID: 30384581    Free PMC article.
Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples.
Aditya Vijay Bhagwate, Yuanhang Liu, +12 authors, Chen Wang.
BMC Genomics, 2019 Sep 04; 20(1). PMID: 31477010    Free PMC article.
PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer.
Michael Rees, Chris Smith, Peter Barrett-Lee, Steve Hiscox.
Oncotarget, 2021 Jan 22; 11(51). PMID: 33473257    Free PMC article.
Targeting RLIP with CRISPR/Cas9 controls tumor growth.
Jyotsana Singhal, Shireen Chikara, +3 authors, Sharad S Singhal.
Carcinogenesis, 2020 May 20; 42(1). PMID: 32426802    Free PMC article.